Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1199266-76-6

Post Buying Request

1199266-76-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1199266-76-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1199266-76-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,9,2,6 and 6 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1199266-76:
(9*1)+(8*1)+(7*9)+(6*9)+(5*2)+(4*6)+(3*6)+(2*7)+(1*6)=206
206 % 10 = 6
So 1199266-76-6 is a valid CAS Registry Number.

1199266-76-6Relevant articles and documents

Kinetics and Mechanism of Bromination of 2-Pyridone and Related Derivatives in Aqueous Solution

Tee, Oswald S.,Paventi, Martino

, p. 4142 - 4146 (1982)

The tautomeric system 2-pyridone 2-hydroxypyridine (1a 2a) reacts with aqueous bromine via the principal tautomer 1a at pH 6.Attack upon 1a occurs preferentially at the 3 position, whereas reaction upon the anion probably involves major attack at the 5 position.The facile dibromination of 2-pyridone results from the comparable reactivity of the monobromopyridones at pH 4.These conclusions are based upon kinetic and product studies of the bromination of 1a and various derivatives in aqueous solutions at pH 0-8.With respect to their reactivity toward bromine the pyridones behave as substituted phenoxide ions.

-

Spinner,White

, p. 991,992 (1966)

-

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

-

Paragraph 0088; 0096, (2020/04/09)

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

Preparation method of 2,5-dimethoxy pyridine

-

Paragraph 0150; 0151; 0152; 0153, (2018/12/13)

The invention discloses a preparation method of 2,5-dimethoxy pyridine, and belongs to the technical field of medicine synthesis. The method comprises the following steps that 1, under the existence of an alcohol solvent, a compound shown as a formula A and sodium methoxide take contact reaction to form a compound shown as a formula B; 2, under the existence of metal catalysts, the compound shownas a formula B in the first step reacts to obtain 2,5-dimethoxy pyridine; aftertreatment and purification are performed to obtain the product. The method has the advantages that the route is short; the steps are few; expensive palladium catalysts and boracic acid catalysts are not used; the equipment cost is reduced; the use of flammable and explosive lithium reagents and peroxide is avoided; thereaction conditions are mild; the aftertreatment operation is simple and convenient; the total yield and the purity are improved; the product quality can be easily controlled; the industrial amplification prospects are good.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1199266-76-6